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ThrombosisThrombotic and cardiovascular events are among the leading causes of death for patientswith polycythemia vera
(PV), and thrombosis history is a key criterion for patient risk stratiﬁcation and treatment strategy. Little is
known, however, about mechanisms of thrombogenesis in patients with PV. This report provides an overview
of thrombogenesis pathophysiology in patients with PV and elucidates the roles of conventional and nonconven-
tional thrombotic risk factors. In addition to several conventional risk factors for thrombosis, clinical data have
implicated increased hematocrit and red blood cell adhesiveness, activated platelets, leukocytosis, and elevated
JAK2V617F allele burden in patients with PV. Furthermore, PV-related inﬂammation may exacerbate
thrombogenesis through varied mechanisms, including endothelial damage, inhibition of natural anticoagulant
pathways, and secretion of procoagulant factors. These ﬁndings suggest a direct link betweenmyeloproliferation
and thrombogenesis in PV, which is likely to provide new opportunities for targeted antithrombotic interven-
tions aimed at decreasing PV-related morbidity and mortality.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Thrombosis is an important complication among patients with poly-
cythemia vera (PV) and thrombotic events reﬂect disease burden and im-
pact clinical outcomes. Roughly one-ﬁfth of patients with PV are
diagnosed with an arterial or venous thrombotic event as a presenting
feature [1,2], and fatal cardiovascular events contribute to the increased
mortality rate amongpatientswith PV [1–4]. Furthermore, healthcare uti-
lization and costs are higher for patientswith PV comparedwith age- and
gender-matched persons in a large US health insurance claims database
[5] and this is driven in part by arterial and venous thrombotic events.
Thrombotic events are so inextricably tied to the pathogenesis of PV
that they are used in guiding patient risk stratiﬁcation and treatment rec-
ommendations. Patients with no history of thrombotic events and who
are b60 years of age are categorized as low risk [6,7], whereas patients
with a history of thrombotic events or are over the age of 59 years are cat-
egorized as high risk [6,7]. Current treatment recommendations suggest
antiplatelet treatment with low-dose aspirin and phlebotomy as ﬁrst-MD Anderson Cancer Center,
418, Houston, TX 77030, USA.
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. This is an open access article underline therapy for low-risk patients [6,7]. For high-risk patients, recommen-
dations also include the use of cytoreductive agents (e.g., hydroxyurea or
interferon-α [IFN-α]) [6–9]. However, none of the currently available
treatment options for PV are designed to target the active Janus kinase
(JAK)/signal transducer and activator of transcription (STAT) signaling
pathway, which over the last 10 years has been identiﬁed as the molecu-
lar etiology of PV [10–13]. Nearly all patients (99%) have an activating
mutation in exon 12 or 14 of JAK2, which most commonly is JAK2V617F
[6,13,14]. Constitutive activation of JAK2 has been associated with unreg-
ulatedhematopoietic proliferation [11–13,15], and JAK2V617F allele burden
is signiﬁcantly correlated with markers of inﬂammation [16]. Inﬂamma-
tion is an important thrombotic risk factor [16].
The risk of thrombotic events and their associated morbidity and
mortality remain a primary concern in patients with PV [6–8] despite
recent advances in understanding how JAK/STAT pathway dysregula-
tion inﬂuences disease origin and progression. The goal of this report
is to provide an overview of mechanisms of thrombogenesis in patients
with PV by considering both conventional and nonconventional throm-
botic risk factors, including correlates of an overactive JAK/STAT
pathway.
2. Thrombosis in patients with polycythemia vera
In 1856, Rudolf Virchow proposed what would later be termed
Virchow's triad, which postulates that venous thromboses occur because
of abnormalities in interactions between the blood vessel wall, blood
constituents, and blood ﬂow [17,18]. Mechanisms underlying arterialthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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complex biochemical pathways regulating ﬁbrin accumulation and the
participation of several cell types, including platelets, endothelial cells
(ECs), and leukocytes [17,19–21]. Perhaps of most importance is
the concept that mechanisms of thrombosis differ depending on the
rheology of the circuit. Arterial thrombosis, because it develops in the
high-resistance, high-ﬂowvasculature, is triggered by platelet adhesion,
activation, and aggregation [22]. In contrast, venous thrombosis, which
develops in a high-capacitance, low-ﬂow vascular circuit, is triggered by
the activation of the soluble coagulation system and the generation of
insoluble ﬁbrin [22].
In patients with PV, thromboses have been reported throughout the
arterial (transient ischemic attack, stroke, acute myocardial infarction,
and peripheral arterial thrombosis) and venous (deep vein thrombosis,
superﬁcial thrombophlebitis, and pulmonary embolism) systems
(Table 1) [23]. Thrombotic events also may occur in the splanchnic vas-
culature in patients with myeloproliferative neoplasms (MPNs) and/or
JAK2mutation. A recent meta-analysis found that 8% to 53% of patients
with hepatic vein thrombosis (Budd–Chiari syndrome) or portal vein
thrombosis who did not have cirrhosis or a biliary malignancy had a
MPN, which was PV in the majority of cases [24].
The rate of nonfatal thrombosis in patients with PV has been esti-
mated at 3.8 per 100 patient-years [23]. Thrombotic events often
occur before diagnosis and increase in frequency in the years immedi-
ately preceding diagnosis [1]. Patient gender may inﬂuence the type of
thrombotic event; arterial thrombosis has been reported to be more
common in men (18% vs 14%; P = 0.02), whereas venous thrombosis
has been reported to be more common in women (9.3% vs 5.4%;
P b 0.01) [2].Table 1
Incidence of thrombotic events in patients with PV.
Reference Patients
n
Thrombotic event Incidence
%
Tefferi et al. [2] 1545 At or before diagnosisa
Arterial 16
Venous 7.4
After diagnosisb
Arterial 12
Venous 9
Marchioli et al. [23] 1638 Nonfatal thrombotic events during
follow-upc
10.3
Arterial thrombosis 5.3
TIA 2.0
Stroke 1.4
Peripheral 1.2
MI 0.9
Venous thrombosis 5.4
Superﬁcial thrombophlebitis 2.8
DVT 2.3
Pulmonary embolism 0.8
Fatal cardiovascular events during
follow-upc
4.5
Coronary heart disease 1.5
Congestive heart failure 0.8
Nonhemorrhagic stroke 0.8
Pulmonary embolism 0.4
Intracranial hemorrhage 0.1
Other cardiac diseases 0.3
Other hemorrhages 0.3
Other vascular deaths 0.3
Gruppo Italiano Studio
Policitemia [1]
1213 Before diagnosisd 14
At diagnosis 20
During follow-upe 19
DVT= deep vein thrombosis; MI=myocardial infarction; PV= polycythemia vera; TIA=
transient ischemic attack.
a The analysiswas initiated in 2010 and includedpatients diagnosedwith PVafter 1970.
b The median (range) follow-up was 6.9 years (0–39.3 years).
c The mean (SD) follow-up was 2.7 (1.3) years.
d Patient histories included ≤33 years before diagnosis.
e The median (range) follow-up was 5.3 years (0–32.9 years).Thrombotic events, in particular arterial thrombosis, may contribute
to an increasedmortality risk in patients with PV. A retrospective Italian
study of 1213 patients reported that 30% of 145 arterial thrombotic
events and 11% of 87 venous thrombotic events were fatal, accounting
for 24% and 6% of all deaths, respectively (median follow-up, 5.3 years
[range, 0–32.9 years]) [1]. A retrospective international study of 1545
patients reported thrombotic complications as the cause of death in
9% of patients (median follow-up, 6.9 years [range, 0–39.3 years]) [2].
Patients with a history of thrombotic events were at further risk for
mortality compared with those who had no such history (hazard ratio
[HR], 1.9; 95% CI, 1.2–3.0; P = 0.007) [2]. These results are consistent
with data from the European Collaboration on Low-Dose Aspirin in
Polycythemia Vera (ECLAP) study showing that a previous thrombosis
doubles PV-associated mortality [23].
3. Thrombotic risk factors
There are few studies elucidating molecular mechanisms of
thrombogenesis in PV. Several clinical studies, however, have identiﬁed
risk factors associated with thrombosis in patients with PV. There are
multiple risk factors, including both conventional risks and PV-speciﬁc
risks such as JAK2V617F allele burden. These latter elements may some-
day inform the design of future studies investigating better treatments
of thrombogenesis in this setting.
3.1. Conventional risk factors
3.1.1. Thrombotic event history
Patients with PV share several thrombotic risk factors with otherwise
healthy individuals (Table 2) [25]. Perhaps of greatest importance is a his-
tory of thrombotic events. The prospective ECLAP study reported in-
creased risk of cardiovascular events among patients with a history of
thrombosis (HR, 2.09; 95% CI, 1.55–2.81) [23] and that risk for major
thrombosis was associated with varied prior thrombotic events (major
thrombosis [HR, 1.69; 95% CI, 1.21–2.36], arterial thrombosis [HR, 1.66;
95% CI, 1.20–2.32], venous thrombosis [HR, 1.74; 95% CI, 1.06–2.87]),
prior stroke or transient ischemic attack (HR, 1.81; 95% CI, 1.27–2.57),
and prior deep vein thrombosis (HR, 2.04; 95% CI, 1.22–3.39) [26].
Large retrospective studies have also reported signiﬁcantly greater risk
for thrombotic events in patients with a history of thrombosis [1,27].
3.1.2. Erythrocytosis
A recent prospective randomized clinical trial analyzed 365 patients
with PV, and identiﬁed a lower incidence of cardiovascular events
among patients who maintained hematocrit b45% compared with 45%
to 50% (4.4% vs 10.9%; P = 0.02) (Table 2) [28]. Furthermore, the
lower hematocrit group was associated with a lower death rate from
cardiovascular causes or major thrombosis (1.1 vs 4.4 per 100 person-
years). This important prospective clinical study clariﬁed the target
hematocrit level for clinicians to pursue in everyday practice. The
issue was previously debated because two retrospective analyses re-
ported no correlation between patient hematocrit and subsequent arte-
rial or venous thrombotic events [27,29]. Further research is necessary
to untangle the complex mechanisms by which small differences in he-
matocrit, which have little effect on viscosity and blood ﬂuidity [30],
could inﬂuence thrombosis in patients with PV.
There may also be qualitative changes in the red blood cells of
patients with PV that promote thrombosis. Recent data suggest that
erythrocytes from patients with PV are more adhesive because
JAK2V617F drives phosphorylation of the red blood cell adhesion receptor
Lutheran/basal cell-adhesionmolecule (Lu/BCAM), which enhances red
blood cell binding to subendothelial laminin [31].
3.1.3. Leukocytosis
In recent years, leukocytosis has emerged as a potential risk factor
for thrombosis in patients with PV. An unadjusted analysis of ECLAP
Table 2
Risk factors for thrombosis in patients with PV.
Reference Analysis type Patients
n
Risk factor for
thrombosis
Comparison P value and/or HR
(95% CI)a
Gangat et al. [27] Retrospective 459 Prior thrombotic event vs no prior thrombotic event P b 0.0001
Landolﬁ et al. [26] Retrospective 1638 vs no prior thrombotic event 1.69 (1.21–2.36)
Marchioli et al. [23] Prospective 1638 vs no prior thrombotic event 2.09 (1.55–2.81)b
Gruppo Italiano [1] Retrospective 1213 vs no prior thrombotic event P= 0.001
Caramazza et al. [32] Prospective 99c Leukocytosis N9.5 × 109/L vs ≤9.5 × 109/L at baseline P= 0.03
1.8 (upper 95% CI, 3.4)
N9.5 × 109/L vs ≤9.5 × 109/L time-dependent analysis No signiﬁcant correlation
1.3 (upper 95% CI, 2.9)
De Stefano et al. [33] Retrospective 235d High vs lowWBC count quartile in patients aged b60 years 3.55 (1.02–12.25)
Landolﬁ et al. [26] Retrospective 1638 N15 × 109/L vs 10.1 to 15 × 109/L P= 0.028
1.56 (1.05–2.30)
Gangat et al. [27] Retrospective 459 ≥15 × 109/L vs b15 × 109/L P= 0.005
Marchioli et al. [28] Prospective,
randomized
365 Elevated hematocrit b45% vs 45% to 50% P= 0.02e
2.69 (1.19–6.12)
Caramazza et al. [32] Prospective 99c ≤45% vs N45% at baseline No signiﬁcant correlation
1.3 (upper 95% CI, 1.8)
≤45% vs N45% time-dependent analysis No signiﬁcant correlation
1.4 (upper 95% CI, 3.3)
Gangat et al. [27] Retrospective 459 Not speciﬁed No signiﬁcant correlation
Di Nisio et al. [29] Retrospective 1638 ≤45% vs 46% to 50% No signiﬁcant correlation
P= 0.5844
0.89 (0.60–1.34)
≤45% vs N50% No signiﬁcant correlation
P= 0.8884
1.04 (0.61–1.78)
Passamonti et al. [14] Prospective 338 JAK2V617F allele burden b50% vs ≥50% No signiﬁcant correlation
P= 0.8
1.0 (0.9–1.0)
Vannucchi et al. [34] Prospective 173 ≤25% vs N75% P= 0.003
7.1f (1.6–10.1)
HR = hazard ratio; PV = polycythemia vera; WBC= white blood cell.
a P value and HR presented when available in the source material.
b Risk of cardiovascular events, deﬁned as cardiovascular death and nonfatal thrombotic events.
c Analyses were conducted on the total patient population, which included 187 patients (PV, n = 99; essential thrombocythemia, n = 88).
d Analyses were conducted on the total patient population, which included 494 patients (PV, n = 235; essential thrombocythemia, n = 259).
e Total cardiovascular events.
f Relative risk for thrombosis during a median follow-up of 24 months.
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follow-up in patients with elevated white blood cell (WBC) counts
(N15 × 109/L vs 10.1 to 15 × 109/L; P = 0.015) that was conﬁrmed in
multivariate analyses adjusted for age, sex, disease duration, prior
thrombosis, prior hemorrhage, conventional risk factors, number of
comorbidities, or cytoreductive and antithrombotic treatment [26]. In
agreement, a prospective study of 187 patients with PV or essential
thrombocythemia (ET) reported increased risk of thrombosis among
patients with a WBC count N9.5 × 109/L (median) at baseline (P =
0.03) [32] and a nonsigniﬁcant trend toward increased thrombotic
risk among patients with leukocytosis in the PV subgroup (P = 0.07).
Finally, a retrospective study of 459 patients with PV reported a signiﬁ-
cant association between baseline leukocyte count ≥15 × 109/L and
venous thrombotic events during a median follow-up of 64 months
(range, 0–562 months; P= 0.005) (Table 2) [27].
The association between leukocyte count and recurrent thrombotic
risk may be limited to patients aged b60 years. A retrospective study
of 494 patients with PV (n = 235) or ET (n = 259) reported increased
risk for recurrent thrombosis in patients with leukocyte count in the
highest versus lowest quartile (HR, 3.55; 95% CI, 1.02–12.25) only for
patients aged b60 years [33].3.1.4. Other conventional risk factors
Several other conventional risk factors have also been reported in
patients with PV. Analysis of the ECLAP study data identiﬁed older age
(N65 years; HR, 2.89; 95% CI, 1.98–4.22) and smoking (HR, 1.55; 95%
CI, 0.99–2.43) as risk factors for major thrombosis [26]. A retrospective
study of 459 patients with PV reported that hypertension and tobaccouse were associated with arterial thrombosis (P ≤ 0.02), and diabetes
mellitus was associated with venous thrombosis (P= 0.002) [27].
3.2. Nonconventional risk factors
3.2.1. JAK2V617F allele burden
The genetic ratio of the JAK2V617F mutation to JAK2 wild-type in
granulocytes, termed the JAK2V617F allele burden [34,35], may also be
prognostic for thrombotic risk (Table 2). Patients with a JAK2V617F allele
burden N75% compared with ≤25% have a seven-fold greater risk for
thrombosis according to a prospective study that followed 173 patients
with PV for amedian of 24months. Although amore recent prospective
study (n=338 patientswith PV followed for amedian of 3.2 years)was
unable to conﬁrm an association between JAK2V617F allele burden and
thrombotic risk, this analysis compared patients with an allele burden
N50% versus ≤50% [14]. Taken together, these results suggest that a
JAK2V617F allele burden threshold between 50% and 75% may identify
patients at high risk for thrombotic events.
JAK2V617Fmay also identify patients speciﬁcally at risk for splanchnic
vein thromboses. A meta-analysis of patients with splanchnic vein
thromboses reported the presence of the JAK2V617F mutation in 26% to
70% of patients with Budd–Chiari syndrome and 10% to 46% of patients
with portal vein thrombosis [24].
3.2.2. Inﬂammation
Inﬂammation may predict thrombosis in patients with PV. A retro-
spective study identiﬁed patients with elevated inﬂammation using
the serum biomarker C-reactive protein (CRP). Patients with high
serum CRP concentration had signiﬁcantly greater risk for thrombosis
218 M.H. Kroll et al. / Blood Reviews 29 (2015) 215–221(P = 0.01) [16], which was conﬁrmed in a multivariable analysis that
adjusted for age, sex, ET or PV diagnosis, cardiovascular risk factors,
JAK2V617F mutation status, and hydroxyurea treatment (all P ≤ 0.045).
3.2.3. Blood cell activation
Laboratory data suggest that activation of leukocytes, platelets, and
ECsmay promote a prothrombotic state [19,36–41]; markers for activa-
tion of these cell types have been observed in patients with PV. A
prospective study of 37 patientswith ET and 34with PV reported signif-
icant elevations in markers for leukocyte activation (CD11b, leukocyte
alkaline phosphatase, elastase activity, plasma elastase, and plasma
myeloperoxidase; P b 0.01) and EC activation (von Willebrand factor
[vWF] and thrombomodulin; P b 0.01) compared with healthy adults
with no history of thrombohemorrhagic events [42]. The aggregation
of leukocytes with platelets is a marker for platelet activation [43] and
is thought to be a key component of leukocyte-driven thrombosis
[44]. A follow-up study that included 34 patients with PV reported in-
creased levels of markers for leukocyte–platelet aggregates (CD11b/
CD42b, CD11b/CD62P; P ≤ 0.001) and a higher percentage of circulating
activated platelets than controls (CD62P; P ≤ 0.001) [43]. In patients
with PV, treatment with hydroxyurea did not inﬂuence marker levels
for leukocyte activation, endothelial activation, or hypercoagulability
[44]. More studies are needed to understand whether these markers
can be used to guide treatment decision making, either with cyto-
reduction, JAK2 inhibition, or with anticoagulation.
A connection between JAK2V617F and platelet activation in human
disease is suggested by a mouse model in which a megakaryocyte-
speciﬁc knock-in of JAK2V617F resulted in the production of platelets
that were hyperreactive to thrombin and collagen [45]. Paradoxically,
these platelets were hyporesponsive to adenosine diphosphate, sug-
gesting that purinergic blockade may be less effective than aspirin for
preventing acute arterial thrombosis in PV [45].
3.2.4. Microparticles
Serum microparticles are small membrane vesicles that are derived
from activated or apoptotic cells, including platelets, monocytes, eryth-
rocytes, and ECs [46]. Among patients with PV, serum microparticles
originating from platelets, erythrocytes, granulocytes, and ECs are ele-
vated compared with healthy controls [47,48]. In particular, patients
with MPNs that had the JAK2V617F mutation had signiﬁcantly higher
plasma concentrations of tissue factor-positive microparticles and
erythrocyte microparticles (P b 0.05) [48]. Among patients with MPNs,
serum concentrations of platelet, erythrocyte, and EC microparticles
were higher in patients with thrombotic complications (P b 0.05) [48].
3.2.5. Coagulation system activation
Patients with PV have demonstrated signiﬁcantly higher levels of
plasma coagulation markers (prothrombin fragment F1 + 2, thrombin–
antithrombin complexes, and D-dimers) than controls (P b 0.05) [42].
Furthermore, the combined coagulant activity of microparticles, erythro-
cytes, and platelets is increased in patients with PV, as evidenced by a
signiﬁcantly reduced clotting time (P b 0.01) [47].
3.3. Proposed mechanism for thrombogenesis in polycythemia vera
Mechanisms of thrombogenesis in patients with PV remain unclear
but appear to be complex, involving multiple components (Fig. 1). Statis-
tically signiﬁcant correlations of JAK2V617F allele burdenwith leukocytosis
and elevated hematocrit suggest that several drivers of thrombogenesis
may be unique to patients with PV [34]. Elevation in hematocrit pushes
platelets closer to the vessel wall and has been shown to increase the
probability of adhesive wall collisions mediated by platelets binding to
vWF and collagen [49,50]. Furthermore, under higher shear conditions,
as exist with elevated hematocrit and in mid-sized arteries affected by
atherothrombotic narrowing, platelets are activated directly [51] and in-
directly through leukocyte–platelet interactions mediated by cathepsinG [41] and CD62P (P-selectin) [52]. In addition, constitutively active
JAK2 signaling may directly drive activation of platelets and granulocytes
[53,54], and indirectly lead to endothelial activation via platelet and leu-
kocyte binding to ECs [39,55,56]. Such interactionsmayprovoke endothe-
lial injury [36,37], endothelial expression of tissue factor [57], and
endothelial release of procoagulant factors such as vWF [38–40]. Further-
more, activated leukocytes, platelets, and ECs secrete microparticles [46],
which express procoagulant factors important for forming the ﬁbrin clot
[46,58]. Finally, inﬂammation in PV may exacerbate the thrombotic
state through varied mechanisms that include endothelial damage
resulting in EC expression of tissue factor, the inhibition of EC-derived
natural anticoagulant pathways, and the secretion of procoagulant fac-
tors, particularly vWF [59].
3.4. Treatment options
Current treatment recommendations for patients with PV are sup-
ported by signiﬁcant reductions in the risk of cardiovascular death and
nonfatal thrombotic events observed in patients receiving antiplatelet
therapy (HR, 0.72; 95% CI, 0.53–0.97; P= 0.0315) and signiﬁcantly re-
duced risk of death from cardiovascular or thrombotic events (HR, 3.91;
95% CI, 1.45–10.53; P=0.007) among patients whomaintained hemato-
crit b45%with phlebotomy, aspirin, and/or cytoreductive agents [28]. Hy-
droxyurea and IFN-α are considered ﬁrst-line therapeutic agents for
patients in need of cytoreduction [60]. Second-line chemotherapeutic
agents, including busulfan or radioactive phosphorus, are rarely used be-
cause of their leukemogenic potential [61,62]. Consensus recommenda-
tions should also be considered to support aggressive control of
conventional thrombotic risk factors like diabetes, hypertension, hyper-
lipidemia and, of course, abstinence from smoking [7,25]. In women,
avoiding hormone-based contraception likely reduces the rate of venous
thromboembolism [25], although clinical trials would be needed to ad-
dress this hypothesis prospectively. Although these interventions ad-
dress the conventional thrombotic risk factors, current treatment
options do not target the underlying molecular cause of PV (i.e., dys-
regulation of the JAK/STAT pathway) or PV-related inﬂammation.
The JAK1/JAK2 inhibitor ruxolitinib was recently approved by the
Food and Drug Administration (FDA) for the treatment of patients
with PVwhohave had an inadequate response to or are intolerant of hy-
droxyurea. Ruxolitinib is also approved by the FDA for the treatment of
intermediate or high-risk myeloﬁbrosis (MF), including primary MF,
post-PV MF, and post-ET MF. The RESPONSE trial compared ruxolitinib
with best available therapy in patients with PV who were intolerant of
or resistant to hydroxyurea. Initial results of the study suggest reduced
thrombotic risk in patients randomized to ruxolitinib compared with
best available therapy (0.9% of patients randomized to ruxolitinib had
a thrombotic event after 32 weeks vs 5.4% randomized to best available
therapy) [63]. The JAK1/JAK2 inhibitor momelotinib (ClinicalTrials.gov
identiﬁer, NCT01998828) is currently in phase 2 clinical trials for pa-
tients with ET or PV. Finally, pegylated (PEG)-IFN-α2a and PEG-IFN-
α2b have been evaluated in phase 2 clinical trials for patients with PV.
One study (n = 37) reported no thrombotic events after a median
follow-up of 31months [64]; two other studies (n=40 and 43) indicat-
ed that 70% and 76% of patients achieved complete response (a compos-
ite endpoint that included absence of thrombosis) after a median
follow-up time of 21 and 42 months, respectively [65,66]. Further stud-
ies will be required to conﬁrm if/how these developing treatment op-
tions affect thrombotic-related outcomes in patients with PV.
4. Future directions
Althoughmany risk factors for thrombosis have been identiﬁed for PV,
several mechanistic questions remain regarding the causal relationship.
Of particular interest is the role of the JAK/STAT pathway andunderstand-
ing the molecular mechanisms of activated JAK2 on blood cell and
vascular activation. It will be important to clarify how thrombogenesis is
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Fig. 1. Proposed mechanism of thrombogenesis in patients with PV. Thrombogenesis in patients with PV is a complex process that involves many components. Future research will be
necessary to conﬁrm and reﬁne this proposed mechanism; however, several drivers of thrombogenesis are depicted in this ﬁgure that may be unique to patients with PV [1]. Under
high hematocrit conditions common in patients with PV, platelets are pushed centrifugally and aremore likely to adhere to vessel wall collagen and vWF, thus initiating thrombus forma-
tion [2]. High shear conditions resulting from vascular damage and elevated blood cell counts directly enhance platelet adhesion and activation, and thereby promote leukocyte–platelet
interactions. These interactions, which are principally mediated by platelet CD62P binding to leukocyte CD11b, result in neutrophil and monocyte activation. Neutrophil activation
ampliﬁes platelet activation through the release of cathepsinG, andmonocyte activation results in its expression of tissue factor, leading to the activation of the soluble coagulation system.
JAK2mutations also promote the direct activation of leukocytes and platelets. Activated platelets and leukocytes bind to and activate ECs, and activated leukocytes, platelets, and ECs
secrete procoagulant microparticles that contribute to formation of the ﬁbrin clot [3]. PV-related blood cell and EC activation, as well as PV-related inﬂammation, results in endothelial
injury. EC injury results in a prothrombotic state through the inhibition of EC-derived natural anticoagulant pathways, and the stimulation of several EC-derived procoagulant factors,
particularly tissue factor and vWF. EC = endothelial cell; PV = polycythemia vera; vWF = von Willebrand factor.
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cles, inﬂammation, and elevated blood cell counts interact with these fac-
tors to promote thrombosis. Such data could have important implications
for guiding future treatment recommendations and for determining if
targeting activated JAK2 is useful for preventing and/or treating PV-
related arterial and venous thrombosis. If JAK2-dependent vascular cell
activation or inﬂammation is the trigger of thrombogenesis in patients
with PV, inhibition of JAK2 activity could be associated with greater
thrombotic beneﬁt than nontargeted treatment options.
5. Conclusions
Thrombogenesis in patients with PV is a complex process that
likely involves synergistic interactions between several blood and
vascular cells. Elevated blood cell counts; JAK2V617F allele burden;
high serum concentration of microparticles; and the activation ofplatelets, leukocytes, and endothelial cells have all been associated
with increased risk of thrombotic events. Clarifying mechanisms of
thrombogenesis in the PV setting is likely to offer opportunities to
improve clinical outcomes for patients with PV and other myelopro-
liferative disorders.Practice points
• Cardiovascular and thrombotic events contribute to the increased
mortality rate among patients with PV compared with the general
population.
• Advanced age, a history of thrombosis, elevated hematocrit, and leu-
kocytosis are risk factors for cardiovascular and thrombotic events in
patients with PV.
• To reduce thrombotic risk, patients with PV should receive aspirin
220 M.H. Kroll et al. / Blood Reviews 29 (2015) 215–221with phlebotomy and/or cytoreductive therapy to maintain hemato-
crit b45%.
Research agenda
• Characterization of mechanistic links between thrombotic risk factors
and hematologic proliferation in PV
• Determination of the prognostic and predictive value of nonconven-
tional risk factors for thrombosis in patients with PV
• Determination of the clinical beneﬁt associated with PV treatment
options that target the underlying causes of PV and thrombosis
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